Makers of the LCDT1:
a Simple Blood Test for Early Detection of Lung Cancer

An early diagnosis for lung cancer can mean a cure.

Insert Video
Insert Video

From the CEO

Lung cancer kills as many people in the US as the next four cancers combined. We wanted to do something about that. For if the lung cancer is detected early, advances in treatments have greatly increased survivability. A lung cancer diagnosis should not be a death sentence as it used to be.  ~Thomas C. Long

Our Process

Develop sensitive and
specific blood test to

DETECT HIGH MORTALITY CANCERS EARLY

Lung Cancer Proteomics has spent 13 years developing a simple blood test that can detect early stage Non-Small Cell Lung Cancer (NSCLC) with high sensitivity and specificity.

​Commit to a

DATA DRIVEN APPROACH AND RIGOROUS SCIENTIFIC PROCESS

We focus on evaluating protein biomarkers in conjunction with proprietary algorithms and patient demographic information to provide a risk assessment for early stage lung cancer.

Simplify and improve diagnostic tools leading to

A BETTER QUALITY OF LIFE FOR CANCER PATIENTS

In 2016, we completed the validation of the Lung Cancer Detection Test 1 (LCDT1). The LCDT1 is a simple blood test that detects Stage 1 lung cancer with high accuracy.

Our Mission

Our mission is to develop sensitive and specific blood tests to detect high mortality cancers early.

Our Strategy

We strictly adhere to a data driven approach and use rigorous scientific processes. We strive to innovate, simplify, and improve early diagnostic tools which lead to a better quality of life for cancer patients and increase survival.


Insert Video

Lung Cancer Proteomics, LLC
Headquarters
105 Washington Street
Michigan City, IN 46360

Bay Area Laboratory
780 Montague Expressway
Building 7, Suite 703
San Jose, CA 95131

LinkedIn - Lung Cancer Proteomics
Twitter - Lung Cancer Proteomics
Facebook - Lung Cancer Proteomics
Insert Video

© 2019 Lung Cancer Proteomics. All rights reserved.